📰 Farrukh Awan News

Farrukh Awan News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Farrukh Awan. Real-time updates on events, politics, business and more.

Bristol Myers Squibb's First Disclosures and New Data at ASH 2023 Highlight Company's Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology -November 02, 2023 at 11:35 am EDT

November 2, 2023

First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® in relapsed or refractory follicular lymphoma demonstrate its...

United States San Diego Sikander Ailawadhi Francesco Passamonti Lisocabtagene Maraleucel Guillaume Cartron

Source: marketscreener.com

Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023

May 11, 2023

First disclosure from Phase 3 COMMANDS study, selected for both ASCO’s official press program and EHA’s plenary session, highlights potential of Reblozyl as first-line treatment of... | May 11, 2023

United States South Korea Andrew Wei Bartl Scott Jean Marie Michot Lorettaj Nastoupil

Source: marketscreener.com

Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023

May 11, 2023

11.05.2023 - Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, the European Hematology Association (EHA) Congress, and the International Conference on Malignant ...

United States South Korea Amit Verma Saloman Manier Alit Taher Andrew Wei

Source: wallstreet-online.de

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Farrukh Awan News Today

Bristol Myers Squibb's First Disclosures and New Data at ASH 2023 Highlight Company's Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology -November 02, 2023 at 11:35 am EDT

Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023

Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023

Explore More Categories